Xeris Biopharma Holdings, Inc. (XERS) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
32.50
-6% vs avg
5yr avg: 34.62
30Y Low34.6·High34.6
P/FCF
45.74
-6% vs avg
5yr avg: 48.55
30Y Low48.6·High48.6
P/B Ratio
↑
93.38
↑+166% vs avg
5yr avg: 35.16
30Y Low2.4·High99.1
ROE
↑
4.0%
↓+103% vs avg
5yr avg: -161.3%
30Y Low-378%·High4%
Debt/EBITDA
1.02
+0% vs avg
5yr avg: 1.02
30Y Low1.0·High1.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
XERS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Xeris Biopharma Holdings, Inc. trades at 2312.5x earnings, 6% below its 5-year average of 2453.1x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.8x, the stock trades at a premium of 10051%. On a free-cash-flow basis, the stock trades at 45.7x P/FCF, 6% below the 5-year average of 48.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.3B | $1.4B | $498M | $324M | $180M | $232M | $210M | $184M | $205M | — | — |
| Enterprise Value | $1.2B | $1.3B | $697M | $485M | $256M | $252M | $259M | $223M | $191M | — | — |
| P/E Ratio → | 2312.50 | 2453.12 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.38 | 4.65 | 2.45 | 1.97 | 1.64 | 4.67 | 10.27 | 67.63 | 83.08 | — | — |
| P/B Ratio | 93.38 | 99.06 | — | — | 3.99 | 2.43 | 6.21 | 12.75 | 2.72 | — | — |
| P/FCF | 45.74 | 48.55 | — | — | — | — | — | — | — | — | — |
| P/OCF | 44.63 | 47.37 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
XERS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Xeris Biopharma Holdings, Inc.'s enterprise value stands at 32.5x EBITDA, 6% below its 5-year average of 34.6x. The Healthcare sector median is 14.6x, placing the stock at a 123% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.40 | 3.43 | 2.96 | 2.33 | 5.09 | 12.69 | 81.87 | 77.47 | — | — |
| EV / EBITDA | 32.50 | 34.62 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 48.37 | 2315.44 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 45.93 | — | — | — | — | — | — | — | — | — |
XERS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Xeris Biopharma Holdings, Inc. earns an operating margin of 8.5%. Operating margins have expanded from -26.8% to 8.5% over the past 3 years, signaling improving operational efficiency. ROE of 4.0% is modest. ROIC of 33.8% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.7% | 81.7% | 81.9% | 82.5% | 79.5% | 73.1% | 54.4% | 41.1% | 98.3% | 99.7% | 99.3% |
| Operating Margin | 8.5% | 8.5% | -16.6% | -26.8% | -74.3% | -232.2% | -408.8% | -4496.0% | -2407.5% | -1711.4% | -1230.8% |
| Net Profit Margin | 0.2% | 0.2% | -27.0% | -38.0% | -85.9% | -247.5% | -446.0% | -4613.5% | -2437.3% | -1706.6% | -1228.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.0% | 4.0% | — | -324.2% | -134.8% | -190.3% | -378.2% | -279.6% | -683.7% | — | — |
| ROA | 0.2% | 0.2% | -17.0% | -18.7% | -29.2% | -53.0% | -68.0% | -109.7% | -72.8% | -67.6% | -39.4% |
| ROIC | 33.8% | 33.8% | -15.5% | -23.9% | -51.8% | -86.7% | -91.9% | -159.9% | — | — | — |
| ROCE | 10.0% | 10.0% | -15.0% | -17.7% | -33.0% | -64.6% | -78.6% | -127.8% | -79.1% | -74.9% | -42.7% |
XERS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Xeris Biopharma Holdings, Inc. carries a Debt/EBITDA ratio of 1.0x, which is manageable (68% below the sector average of 3.2x). The company holds a net cash position — cash of $111M exceeds total debt of $38M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of just 0.0x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.76 | 2.76 | — | — | 4.38 | 0.92 | 2.58 | 4.04 | 0.42 | — | — |
| Debt / EBITDA | 1.02 | 1.02 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -5.35 | — | — | 1.68 | 0.22 | 1.46 | 2.69 | -0.18 | — | — |
| Net Debt / EBITDA | -1.98 | -1.98 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -2.62 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 0.02 | 0.02 | -0.80 | -1.39 | -5.81 | -16.09 | -10.95 | -16.60 | -22.61 | -13277.00 | -6603.50 |
Net cash position: cash ($111M) exceeds total debt ($38M)
XERS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Xeris Biopharma Holdings, Inc.'s current ratio of 2.19x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.57x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.64x to 2.19x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.19 | 2.19 | 1.67 | 1.64 | 2.54 | 1.80 | 5.40 | 3.20 | 11.59 | 9.06 | 13.13 |
| Quick Ratio | 1.57 | 1.57 | 1.19 | 1.23 | 2.20 | 1.57 | 5.10 | 3.12 | 11.59 | 9.06 | 13.13 |
| Cash Ratio | 1.01 | 1.01 | 0.71 | 0.76 | 1.66 | 1.30 | 4.74 | 2.76 | 11.07 | 8.65 | 12.77 |
| Asset Turnover | — | 0.76 | 0.63 | 0.51 | 0.32 | 0.16 | 0.13 | 0.02 | 0.02 | 0.03 | 0.03 |
| Inventory Turnover | 0.78 | 0.78 | 0.76 | 0.74 | 0.92 | 0.74 | 1.12 | 0.74 | — | — | — |
| Days Sales Outstanding | — | 63.85 | 72.64 | 87.28 | 102.07 | 128.48 | 122.80 | 629.30 | 424.82 | 281.26 | 34.29 |
XERS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Xeris Biopharma Holdings, Inc. returns 0.9% to shareholders annually primarily through share buybacks. The earnings yield of 0.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 2.2% | 2.1% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.9% | 0.8% | 0.8% | 0.3% | 0.3% | 0.2% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.9% | 0.8% | 0.8% | 0.3% | 0.3% | 0.2% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $173M | $147M | $138M | $136M | $79M | $43M | $26M | $12M | $2M | $2M |
Peer Comparison
Compare XERS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 XERSYou | $1B | 2312.5 | 32.5 | 45.7 | 81.7% | 8.5% | 4.0% | 33.8% | 1.0 |
 LNTH | $7B | 32.0 | 17.7 | 20.0 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 SUPN | $3B | -65.8 | 45.5 | 56.0 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 PAHC | $1B | 26.7 | 12.7 | 30.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 CORT | $9B | 103.4 | 192.4 | 64.2 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
 AMRX | $6B | 78.7 | 12.3 | 20.5 | 37.6% | 14.0% | 1208.4% | 13.0% | 4.2 |
 NVO | $212B | 13.6 | 10.0 | 48.0 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 |
 LLY | $1.1T | 49.2 | 35.3 | 118.9 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 IONS | $13B | -32.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 PRAX | $9B | -24.3 | — | — | — | — | -45.8% | -65.0% | — |
 NKTR | $1B | -6.4 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
| Healthcare Median | — | 22.8 | 14.6 | 19.4 | 63.6% | -4.8% | -33.2% | -11.3% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
XERS — Frequently Asked Questions
Quick answers to the most common questions about buying XERS stock.
What is Xeris Biopharma Holdings, Inc.'s P/E ratio?
Xeris Biopharma Holdings, Inc.'s current P/E ratio is 2312.5x. This places it at the 50th percentile of its historical range.
What is Xeris Biopharma Holdings, Inc.'s EV/EBITDA?
Xeris Biopharma Holdings, Inc.'s current EV/EBITDA is 32.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 34.6x.
What is Xeris Biopharma Holdings, Inc.'s ROE?
Xeris Biopharma Holdings, Inc.'s return on equity (ROE) is 4.0%. The historical average is -217.2%.
Is XERS stock overvalued?
Based on historical data, Xeris Biopharma Holdings, Inc. is trading at a P/E of 2312.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Xeris Biopharma Holdings, Inc.'s profit margins?
Xeris Biopharma Holdings, Inc. has 81.7% gross margin and 8.5% operating margin.
How much debt does Xeris Biopharma Holdings, Inc. have?
Xeris Biopharma Holdings, Inc.'s Debt/EBITDA ratio is 1.0x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.